What were the findings from the CAHtalyst trial in terms of the ability of the CRF1 receptor antagonist crinecerfont to reduce hydrocortisone dose while maintaining acceptable androstenedione levels?

Patricia Fechner, MD

Medical Director, DSD Program
Medical Director, CAH Program
Co-Director, Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington School of Medicine
Seattle, WA